Stockholders approve amendment to 2023 Equity Incentive Plan, releasing 1.5M restricted shares

Envoy Medical, Inc.

Amendment removes regulatory-milestone restriction on 1,500,000 shares, making them available for issuance under the 2023 Plan.
Vote: 12,332,451 For, 658,102 Against, 20,782 Abstain, 29,189 Broker Non-Votes; amendment effective immediately.
Elected directors Janis Smith-Gomez (12,636,087 For) and Chuck Brynelsen (12,307,953 For) to Class II, term until 2028 annual meeting.
Ratified Grant Thornton LLP as independent auditor for FY2025; approved non-binding advisory vote on named executive officer compensation.

item 5.02item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.